Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin [Yahoo! Finance]
Matinas Biopharma Holdings, Inc. (MTNB)
NASDAQ:AMEX Investor Relations:
ir.matinasbiopharma.com
Company Research
Source: Yahoo! Finance
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, will be featured in a fireside chat with David S. Perlin, PhD , a recognized expert in antifungals. The event is being sponsored by Alliance Global Partners (A.G.P.) and hosted by Scott Henry, A.G.P. Managing Director and Senior Research Analyst. Topics of discussion will include an overview of the antifungal market and current treatment options, the clinical potential of MAT2203 as an oral formulation of amphotericin B, the market potential of MAT2203 and the design and key factors in the MAT2203 ORALTO pivotal trial in patients with invasive aspergillosis who have limited treatment options. Event: Fireside Chat with Dr. David Perlin
Show less
Read more
Impact Snapshot
Event Time:
MTNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MTNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MTNB alerts
High impacting Matinas Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
MTNB
News
- Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. PerlinGlobeNewswire
- New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 [Yahoo! Finance]Yahoo! Finance
- New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024GlobeNewswire
- Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update [Yahoo! Finance]Yahoo! Finance
- Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business UpdateGlobeNewswire
MTNB
Sec Filings
- 5/9/24 - Form 8-K
- 5/9/24 - Form 10-Q
- 4/5/24 - Form 8-K
- MTNB's page on the SEC website